Who
Linda M. Richardson
Chief Commercial Officer
Company insider
Files Form 4 as: Chief Commercial Officer, Altimmune; EVP & Chief Commercial Officer, Intercept Pharmaceuticals; Chief Commercial Officer, Chimerix.
In numbers
- Trades disclosed
- 47
- Buys
- 0
- Sells
- 1
- Bought
- $0
- Sold
- $89K
- Companies
- 3
- Companies where not an officer
- 0
- First trade
- 8 Jan 2014
- Last trade
- 16 Sep 2026
- Last filed
- 17 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 16 Sep 2026filed 17 Sep 2026 | ALT AltimmuneBiotechnology | SEC FORM 4 Code M | —24,000 at $0.00 | filing |
| 16 Sep 2026filed 17 Sep 2026 | ALT AltimmuneBiotechnology | SEC FORM 4 Code F | $22K6,826 at $3.24 | filing |
| 16 Sep 2026filed 17 Sep 2026 | ALT Altimmuneoption or derivative · Biotechnology | SEC FORM 4 Code M | —24,000 at $0.00 | filing |
| 16 Sep 2026filed 17 Sep 2026 | ALT Altimmuneoption or derivative · Biotechnology | SEC FORM 4 Code M | —24,000 at $0.00 | filing |
| 16 Sep 2026filed 17 Sep 2026 | ALT AltimmuneBiotechnology | SEC FORM 4 Code M | —24,000 at $0.00 | filing |
| 16 Sep 2026filed 17 Sep 2026 | ALT AltimmuneBiotechnology | SEC FORM 4 Code F | $22K6,826 at $3.24 | filing |
| 16 Sep 2025filed 17 Sep 2025 | ALT Altimmuneoption or derivative · Biotechnology | SEC FORM 4 Code A | —278,000 at $0.00 | filing |
| 16 Sep 2025filed 17 Sep 2025 | ALT Altimmuneoption or derivative · Biotechnology | SEC FORM 4 Code A | —96,000 at $0.00 | filing |
| 8 Nov 2023filed 13 Nov 2023 | Intercept Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —17,600 | filing |
| 8 Nov 2023filed 13 Nov 2023 | Intercept Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —20,000 | filing |
| 8 Nov 2023filed 13 Nov 2023 | Intercept Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —3,912 | filing |
| 8 Nov 2023filed 13 Nov 2023 | Intercept Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —8,368 | filing |
| 8 Nov 2023filed 13 Nov 2023 | Intercept Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —5,000 | filing |
| 8 Nov 2023filed 13 Nov 2023 | Intercept Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —5,896 | filing |
| 8 Nov 2023filed 13 Nov 2023 | Intercept Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —9,500 | filing |
| 8 Nov 2023filed 13 Nov 2023 | Intercept Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —8,500 | filing |
| 8 Nov 2023filed 13 Nov 2023 | Intercept Pharmaceuticals | SEC FORM 4 Code U | $317K16,706 at $19.00 | filing |
| 8 Nov 2023filed 13 Nov 2023 | Intercept Pharmaceuticals | SEC FORM 4 Code D | $505K26,585 at $19.00 | filing |
| 14 Feb 2023filed 16 Feb 2023 | Intercept Pharmaceuticals | SEC FORM 4 Code F | $8,187386 at $21.21 | filing |
| 27 Jan 2023filed 31 Jan 2023 | Intercept Pharmaceuticalsoption or derivative | SEC FORM 4 Code A | —20,000 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.